Skip to main content
BNTX
NASDAQ Life Sciences

CEO-affiliated entity files intent to sell $93.8M in BioNTech shares

Analysis by Wiseek.ai
Sentiment info
Negative
Importance info
8
Price
$109.38
Mkt Cap
$26.301B
52W Low
$81.2
52W High
$124.487
Market data snapshot near publication time

summarizeSummary

Medine GmbH, an entity associated with CEO Ugur Sahin and listed as an officer and 10% stockholder, has filed a Form 144 indicating an intent to sell approximately $93.87 million worth of BioNTech SE shares.


check_boxKey Events

  • Proposed Sale by CEO-Affiliated Entity

    Medine GmbH, an entity associated with CEO Ugur Sahin and identified as an officer and 10% stockholder, filed a Form 144 for the proposed sale of 858,209 shares.

  • Substantial Market Value

    The proposed sale has an approximate market value of $93.87 million, indicating a significant potential disposition of shares.

  • Prior Sales by CEO

    This filing follows previous sales by Ugur Sahin totaling $29.03 million over the past three months, as detailed in the filing, suggesting a pattern of insider selling.


auto_awesomeAnalysis

This Form 144 signals a substantial potential disposition of shares by Medine GmbH, an entity affiliated with BioNTech's CEO, Ugur Sahin, who is also identified as an officer and 10% stockholder. The proposed sale of over $93 million represents a notable transaction, especially following a series of positive strategic updates from the company in January. While a Form 144 is an intent to sell and not a guaranteed sale, such a large filing from a key insider can be perceived negatively by the market, suggesting a potential reduction in exposure by a significant stakeholder. This filing also follows prior sales by Ugur Sahin totaling over $29 million in the past three months. Investors will monitor subsequent Form 4 filings to confirm if and when these shares are actually sold.

At the time of this filing, BNTX was trading at $109.38 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $26.3B. The 52-week trading range was $81.20 to $124.49. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.

descriptionView Main SEC Filing

show_chartPrice Chart

Share this article

Copied!

feed BNTX - Latest Insights

BNTX
Apr 11, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
BNTX
Apr 02, 2026, 4:15 PM EDT
Filing Type: 6-K
Importance Score:
8
BNTX
Mar 24, 2026, 6:45 AM EDT
Source: GlobeNewswire
Importance Score:
8
BNTX
Mar 10, 2026, 6:55 AM EDT
Filing Type: 20-F
Importance Score:
7
BNTX
Mar 10, 2026, 6:54 AM EDT
Source: Reuters
Importance Score:
8
BNTX
Mar 10, 2026, 6:53 AM EDT
Filing Type: 6-K
Importance Score:
8
BNTX
Mar 10, 2026, 6:45 AM EDT
Source: GlobeNewswire
Importance Score:
8
BNTX
Mar 10, 2026, 6:34 AM EDT
Filing Type: 6-K
Importance Score:
8
BNTX
Mar 10, 2026, 6:30 AM EDT
Source: Dow Jones Newswires
Importance Score:
7
BNTX
Feb 12, 2026, 8:17 AM EST
Filing Type: 144
Importance Score:
8